Compare · LH vs NEUE
LH vs NEUE
Side-by-side comparison of Labcorp Holdings Inc. (LH) and NeueHealth Inc. (NEUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LH and NEUE operate in Medical Specialities (Health Care), so they compete in similar markets.
- LH carries a market cap of $25.85B.
- Over the past year, LH is up 14.6% and NEUE is up 1.2% - LH leads by 13.5 points.
- LH has hit the wire 7 times in the past 4 weeks while NEUE has been quiet.
- LH has more recent analyst coverage (25 ratings vs 0 for NEUE).
- Company
- Labcorp Holdings Inc.
- NeueHealth Inc.
- Price
- $263.82-0.44%
- $6.84+2.09%
- Market cap
- $25.85B
- -
- 1M return
- -0.86%
- +2.09%
- 1Y return
- +14.64%
- +1.18%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 0
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest LH
- Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
- Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes
- Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research
- SEC Form DEFA14A filed by Labcorp Holdings Inc.
- SEC Form DEF 14A filed by Labcorp Holdings Inc.
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp Declares Quarterly Dividend
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Announce First Quarter Financial Results on April 30, 2026
- SEC Form 4 filed by Schechter Adam H
Latest NEUE
- Chief Financial Officer Matushak Jay returned 40,431 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 15-12G filed by NeueHealth Inc.
- Large owner Bessemer Venture Partners Ix L.P. returned 999,218 shares to the company (SEC Form 4)
- Director Kraus Stephen returned 16,443 shares to the company, closing all direct ownership in the company (SEC Form 4)
- GC & Corporate Secretary Craig Jeffery Michael returned 20,103 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, Consumer Care Orozco Tomas returned 29,325 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sheehy Robert J returned 265,945 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Adkins Kedrick D Jr returned 16,443 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Kadre Manuel returned 33,505 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Slavitt Andrew M returned 107,809 shares to the company, closing all direct ownership in the company (SEC Form 4)